Close collaboration with a comprehensive team of medical experts is essential to the work of the European Haemophilia Consortium (EHC). In addition to our already established committees, in 2017 the Medical and Scientific Advisory Group (MASAG) was formed with the objective to:

  • Help ensure a multidisciplinary approach to the work of the EHC,
  • Provide advice and guidance on specific areas of EHC engagement,
  • Provide strategic input into specific event programmes and activities as necessary, and
  • Provide hands-on, in-person support in key events as needed

The Medical and Scientific Advisory Group is composed of:

      • Rezan Abdul-Kadir
        Consultant Gynecologist with a subspecialty in fetal medicine
        Royal Free NHS Foundation Trust, London, UK
      • Massimo Colombo 
        Hepatologist and Director of the Center for Translational Research in Liver Disease at the Humanitas Research Hospital
        Rozzano, Italy
      • Piet De Klein
        University Medical Centre Utrecht, the Netherlands
      • Roseline d’Oiron
        Clinician investigator
        Reference Centre for Haemophilia and Other Congenital Rare Bleeding Disorders, Congenital Platelet Disorders and von Willebrand Disease at Bicêtre Hospital AP-HP, Paris XI University, Le Kremlin-Bicêtre, France
      • Alison Dougall 
        Dentist and clinical consultant in special care dentistry
        Dublin Dental University Hospital
        Dublin, Ireland
      • Carmen Escuriola-Ettinghausen 
        Paediatrician and Director of the Haemophilia Centre Rhein Main
        Frankfurt, Germany
      • Albert Farruggia 
        Professor Faculty of Health and Medical Science
        The University of Western Australia, Perth, Australia.
      • Dan Hart 
        Immunologist, senior lecturer in haematology and immunobiology at Barts and The London School of Medicine, Queen Mary University London and Honorary Consultant Haematologist at The Royal London Hospital Haemophilia Centre, Barts Health NHS Trust
        London, United Kingdom
      • Anneliese Hilger  
        Regulatory Advisor, head of “Blood Coagulation Products” section at the Paul-Ehrlich-Institut
        Langen, Germany
      • Vince Jenkins 
        Laboratory Head specialized in haemostasis diagnosis and research
        University Hospital of Wales, Cardiff, UK
      • Evelien Mauser-Bunschoten 
        Haemophilia Specialist
        University Medical Centre, Utrecht, the Netherlands
      • Giuseppe Mazza
        National Institute for Health and Research British Research Council Post-Doctoral Fellow at the UCL Institute for Liver and Digestive Health, co-founder, CEO and CSO at Engitix Ltd.
        London, United Kingdom
      • Alec Miners
        Economist and Associate Professor of Health Economics at the London School of Hygiene and Tropical Medicine
        London, United Kingdom
      • Beatrice Nolan
        Paediatrician and Lead Consultant Haematologist in relation to paediatric haemophilia and allied bleeding disorders at Our Lady’s Children’s Hospital in Crumlin
        Dublin, Ireland
      • Cristina Novembrino 
        Laboratory Scientist and researcher focusing on diagnostic activity and management of research protocols in thrombosis and haemostasis at the Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico
        Milan, Italy
      • Jamie O’Hara
        Health Economist, health economic lead on an expert panel piloting proof of concept for the development and implementation of a global haemophilia registry and Senior Lecturer in Health Economics at the University of Chester
        Chester, United Kingdom
      • Brian O’Mahony
        Brian is the former President of the European Haemophilia Consortium (EHC) and the Chief Executive of the Irish Haemophilia Society.
      • Debra Pollard
        Lead Nurse at the Katharine Dormandy Haemophilia & Thrombosis Centre at the Royal Free Hospital
        London, United Kingdom
      • Frits Rosendaal 
        Epidemiologist and professor of clinical epidemiology at the Leiden University Medical Centre
        Leiden, Netherlands
      • Glenda Silvester
        Regulatory Advisor previously worked for 18 years at the European Medicines Agency (EMA), where she was the lead for blood products. She was Scientific Secretary of the Blood Products Working Party, which provides recommendations on matters relating to the efficacy and safety of blood products.
        London, United Kingdom
      • Luigi Solimeno
        Director, Emergency and Trauma Department, Rare Disease Service
        IRCCS Cà Grande Foundation, Milan, Italy
      • Thierry Vanden Driessche 
        Director, Department of Gene Therapy and Regenerative Medicine
        Free University (VUB), Brussels, Belgium